ClinicalTrials.gg
RecruitingNCT06790082FAPI-PMUpdated Nov 2, 2026

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

A Phase 2 interventional study of [68Ga]Ga-FAPI-46 PET/CT in Pleural Mesothelioma, Pleural Diseases and Cancer, sponsored by Aalborg University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Aalborg University Hospital · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.

The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard.

For patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET/CT and an additional FDG PET/CT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET/CT in response evaluation will be investigated.

All study specific analyzes will be blinded and will not influence the patient management / treatment.

Read the detailed description

A new and promising PET tracer has been developed: Gallium-68 labelled fibroblast activation protein inhibitor (FAPI). FAPI binds to fibroblast activation protein (FAP), a type II transmembrane protein, which is expressed and upregulated in cancer associated fibroblasts. FAPI PET/CT has been superior to FDG PET/CT regarding tumor detection rate in multiple cancer entities. When evaluating the clinical value of FAPI PET/CT compared to conventional imaging, including FDG PET/CT, studies have shown that FAPI PET/CT led to a revised staging in up to 25-30% of cancer patients, and a revised treatment in up to 20-30% of patients. The clinical interest in FAPI extends beyond the use as a diagnostic tool, as the 68Ga-isotope can be replaced by a β-emitting isotope, e.g., 177-Lu or 90-Y, enabling radionuclide therapy of FAPI-avid cancers.

FAP-immunohistochemistry (FAP-IHC) studies in PM have shown promising results, and - as PM is of mesodermal origin, FAP-overexpression has been observed in the cancer cells themselves.

To date, only two clinical FAPI PET study in PM has been conducted. In these studies uptake values were significantly higher for FAPI PET compared to FDG PET regarding primary tumors and lymph node metastases. Moreover, FAPI PET/CT led to upstaging in some of the patients compared to FDG PET/CT.

Based on pathological studies, implementation of FAPI PET/CT could be particularly beneficial in sarcomatoid and biphasic PM subtypes, which are characterized by aggressive growth and a worse prognosis compared to the epithelioid subtypes, however, non-epithelioid subtypes are underrepresented in FAPI PET studies to date.

PM in most cases is diagnosed at advanced stages of the disease and surgery with pleurectomy/decortication is only indicated in select cases with localized disease (approx. 30% of patients with the epithelioid subtype). Therefore, most patients undergo palliative treatment with either chemotherapy, immunotherapy, or radiotherapy. Considering the inherent limitations and difficulties for CT based response evaluation tools in PM, experts argue that response assessment using FDG PET/CT, i.e., PET Response Evaluation Criteria in Solid Tumors (PERCIST), could be an even more sensitive tool in PM compared to anatomical imaging response tools.

To date, there are no studies evaluating the feasibility of FAPI PET for response assessment in PM.

The study is a prospective explorative study complying with the Standard for Reporting Diagnostic Accuracy (STARD) criteria where 70 patients with suspected PM are recruited.

An additional FAPI PET/CT will be performed as a study specific procedure at primary staging within 4 weeks of the primary staging FDG PET/CT and prior to the pleural biopsy. All included study subjects will undergo this additional primary staging FAPI PET/CT. Patients with benign histology will not receive any further study related procedures - unless they are re-recruited at a later time point. For the proportion of study subjects treated with chemotherapy or immunotherapy (anticancer treatment), as part of common clinical practice, additional study specific FAPI PET/CT and FDG PET/CT will be conducted after completing 2-3 series of anticancer treatment, that is 3 series of chemotherapy or 2 series of immunotherapy.

The study specific procedures will be conducted in addition to common clinical practice and will not interfere with or delay the routine diagnostic workup or treatment. The results of the study specific procedures will not be available to the patient or the treating physicians (blinded) and will not interfere with planned treatment/diagnostics.

02

Conditions studied

  • Pleural Mesothelioma
  • Pleural Diseases
  • Cancer
  • FAPI
  • Fibroblast Activation Protein Inhibitor

Keywords

  • FAPI
  • 68Ga-FAPI-46
  • PET/CT
  • Pleural Mesothelioma
  • FDG PET/CT
03

In context

Mesothelioma, Malignant

340 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

This study's planned enrollment of 70 is above the median of 39 across 272 interventional studies indexed under Mesothelioma, Malignant.

Browse Mesothelioma, Malignant studies →

Lead sponsor

Aalborg University Hospital is the lead sponsor of 199 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural .
  • Undergone/undergoing FDG PET/CT as part of the diagnostic workup of a suspicious PM lesion.
  • Considered physically and mentally able to participate in the research project.
  • Understands the study subject information and able to consent to project participation.
  • 18-years or older

Exclusion criteria

Exclusion Criteria:

  • Patients with an imminent need for surgery or in an emergency
  • Known concurrent other with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt.
  • Pregnant or breastfeeding women.
  • Fertile women (women of ) who could - theoretically - be pregnant (i.e., unknown pregnancy status).

Fertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET/CTs, both at primary staging and restaging. Study subjects can participate in the study if the pregnancy test is negative (i.e., not pregnant).

  • Subjects unable to undergo PET/CT: e.g., weighing more than 180 kg (weight limit scanner), unable to fit within the imaging gantry, inability to remain still for the duration of the examination, or with known severe claustrophobia unresponsive to oral anxiolytics or severe fear of needles.
  • Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.
  • History of allergic reactions / attributed to [18F]FDG or FAPI-tracers.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Suspected pleural mesothelioma

    Patients with suspected pleural mesotheliom undergo an additional study specific \[68Ga\]Ga-FAPI-46 PET/CT at primary staging.

    Drug: [68Ga]Ga-FAPI-46 PET/CT

Interventions

  • Drug[68Ga]Ga-FAPI-46 PET/CT

    Drug page: Gallium-68Studies of Gallium-68Gallium-68 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging. The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment.

    Also known as: [68Ga]Gallium - Fibroblast Activation Protein Inhibitor-46 Positron Emission Tomography / Computer Tomography

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance

    The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy - all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions.

    Time frame: 2 years

Secondary outcomes

  1. Location biopsy

    Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT.

    Time frame: 2 years

  2. Staging

    Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary staging.

    Time frame: 2 years

  3. Patient Management

    Calculate the proportion of patients with suspected PM lesion with a change in treatment following the -hypothetical - addition of FAPI PET/CT at primary staging.

    Time frame: 2 years

  4. Uptake Values

    Investigate the FAPI PET uptake parameters in suspicious PM lesions (primary tumor), regional lymph nodes, and distant metastases, and in benign lesions. Correlate FAPI uptake parameters in different PM sutypes.

    Time frame: 2.5 years

  5. Changes uptake parameters due to anticancer treatment

    Calculate changes in FAPI PET uptake parameters - from before to after 2-3 series of anticancer treatment. Changes will be presented as ratios and in %.

    Time frame: 2.5 years

  6. Correlate immunohistochemistry

    Correlate the FAPI PET SUV to FAP targeting immunohistochemistry of biological material.

    Time frame: 5 years

  7. Incidental findings

    Seek supplementary information in medical records, biochemistry, pathology, or other imaging modalities for a final diagnosis/condition in cases of unexpected FAPI PET/CT findings.

    Time frame: 3 years

  8. Safety Evaluation FAPI-injection

    Report Incidence Treatment-Emergent Adverse Events

    Time frame: 2.5 years

  9. Overall survival

    A 10 year follow up of included patients will be conducted to determine overall survival (OS) in days from diagnosis, correlated to FAPI PET/CT results.

    Time frame: 10 years

  10. Recurrence/Progression Free Survival

    A 10 year follow up of included patients will be conducted to determine Recurrence Free Survival (RFS) and Progression Free Survival (PFS) in days from diagnosis, correlated to FAPI PET/CT results.

    Time frame: 10 years

  11. Response evaluation

    Compare conventional CT-based response assessment (mRECIST/iRECIST) to PET based response assessment (PERCIST, and other FDG and FAPI PET derived data) to the clinical outcome, i.e., OS, RFS/PFS.

    Time frame: 10 years

  12. Interobserver reliability

    Conduct an interobserver study of FAPI PET/CTs. Cohens Kappa d will be calculated.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Guglielmo P, Crivellaro C, Castello A, Della Corte CM, Pagano M, Marchesi S, Occhipinti M, Zucali PA, Evangelista L. Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives. Mol Diagn Ther. 2025 Jan;29(1):55-66. doi: 10.1007/s40291-024-00756-4. Epub 2024 Nov 8. PubMed 39514167 ↗
  • Guzel Y, Komek H, Can C, Kaplan I, Kepenek F, Ebinc S, Buyukdeniz MP, Gundogan C, Oruc Z. Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma. Nucl Med Commun. 2023 Jul 1;44(7):631-639. doi: 10.1097/MNM.0000000000001702. Epub 2023 Apr 28. PubMed 37114422 ↗
  • Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, Schaarschmidt B, Wiesweg M, Aigner C, Plones T, Darwiche K, Bolukbas S, Stuschke M, Umutlu L, Nader M, Theegarten D, Hamacher R, Eberhardt WEE, Schuler M, Herrmann K, Fendler WP, Hautzel H. Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial. J Nucl Med. 2024 Aug 1;65(8):1188-1193. doi: 10.2967/jnumed.124.267473. PubMed 38960716 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2027, 27 months after the start.

Of 41 non-industry phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 100. This study's planned 27 months is below that.

Counting every sponsor, half of 48 studies reached it within 48 months; a quarter within 29 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 23, 2025
StartActual
Jan 29, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2037
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06790082
Responsible party
Morten Bentestuen (Principal Investigator, Aalborg University Hospital) — Principal investigator
First posted
Jan 23, 2025
Start date
Jan 29, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2037 (estimated)
Last update
Nov 2, 2026

Study contacts

Morten Bentestuen, MD
Contact
m.bentestuen@rn.dk
+45 97665500
Helle Zacho, MD, DMSc
study director · Clinical Professor dept. of Nuclear Medicine, Aalborg University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion